论文部分内容阅读
目的观察依达拉奉联合血塞通治疗急性脑梗死的临床疗效及其安全性。方法将收治的急性脑梗死患者76例随机分为治疗组(39例)和对照组(37例),对照组使用血塞通等常规治疗,治疗组在对照组治疗基础上,给予依达拉奉30mg加生理盐水100ml静脉滴注,2次/d,共14d。所有病例于治疗前和治疗14d后采用美国国立卫生研究院卒中量表(NIHSS)进行神经功能缺损评分。结果治疗后治疗组的神经功能缺损评分明显低于对照组,治疗组临床疗效明显优于对照组,两组比较差异有统计学意义(P<0.05)。结论血塞通联合依达拉奉治疗急性脑梗死更安全有效,能改善患者的预后。
Objective To observe the clinical efficacy and safety of edaravone combined with Xuesaitong in the treatment of acute cerebral infarction. Methods A total of 76 patients with acute cerebral infarction were randomly divided into treatment group (39 cases) and control group (37 cases). The control group was treated with Xuesaitong and other conventional treatments. The treatment group was treated with control group, In 30mg plus saline 100ml intravenous infusion, 2 times / d, a total of 14d. All cases were scored for neurological deficits using the National Institutes of Health Stroke Scale (NIHSS) before treatment and after 14 days of treatment. Results After treatment, the score of neurological deficit in the treatment group was significantly lower than that of the control group. The clinical curative effect of the treatment group was obviously better than that of the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion Xuesaitong combined with edaravone in the treatment of acute cerebral infarction is more safe and effective, can improve the prognosis of patients.